These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16279094)

  • 21. Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?
    O'Neil BH; McLeod HL
    J Clin Oncol; 2006 Sep; 24(25):4051-3. PubMed ID: 16943521
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
    Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
    Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
    Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
    J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
    Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
    Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
    Garcia AA; Blessing JA; Darcy KM; Lenz HJ; Zhang W; Hannigan E; Moore DH
    Gynecol Oncol; 2007 Mar; 104(3):572-9. PubMed ID: 17049588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.
    Huang CL; Yokomise H; Kobayashi S; Fukushima M; Hitomi S; Wada H
    Int J Oncol; 2000 Jul; 17(1):47-54. PubMed ID: 10853017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.
    Ijuin T; Nibu K; Doi K; Inoue H; Saitoh M; Ohtsuki N; Makino K; Amatsu M
    Acta Otolaryngol; 2007 Mar; 127(3):305-11. PubMed ID: 17364369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes.
    Macpherson JS; Jodrell DI; Guichard SM
    Anal Biochem; 2006 Mar; 350(1):71-80. PubMed ID: 16438929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
    Zhao HY; Huang H; Hu ZH; Huang Y; Lin SX; Tian Y; Lin TY
    Anticancer Drugs; 2012 Jun; 23(5):534-42. PubMed ID: 22481060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
    Tokunaga Y; Takahashi K; Saito T
    Hepatogastroenterology; 2005; 52(66):1715-21. PubMed ID: 16334763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
    Donada M; Bonin S; Nardon E; De Pellegrin A; Decorti G; Stanta G
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):201-10. PubMed ID: 20387074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
    Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
    Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
    Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
    Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
    Kinoshita M; Kodera Y; Hibi K; Nakayama G; Inoue T; Ohashi N; Ito Y; Koike M; Fujiwara M; Nakao A
    Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
    Tahara M; Ochiai A; Fujimoto J; Boku N; Yasui W; Ohtsu A; Tahara E; Yoshida S
    Oncol Rep; 2004 Jan; 11(1):9-15. PubMed ID: 14654896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
    Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
    Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
    Ishihama H; Chida M; Araki O; Karube Y; Seki N; Tamura M; Umezu H; Honma K; Masawa N; Miyoshi S
    Jpn J Clin Oncol; 2009 Jan; 39(1):33-6. PubMed ID: 19015148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
    Salgado J; Zabalegui N; Gil C; Monreal I; Rodríguez J; García-Foncillas J
    Oncol Rep; 2007 Feb; 17(2):325-8. PubMed ID: 17203168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
    Kocakova I; Svoboda M; Kubosova K; Chrenko V; Roubalova E; Krejci E; Sefr R; Slampa P; Frgala T; Zaloudik J
    Neoplasma; 2007; 54(5):447-53. PubMed ID: 17688376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.